Keyphrases
Nivolumab
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Real-life Data
100%
Overall Survival
60%
ECOG PS 2
60%
Real-life Setting
40%
Overall Response Rate
40%
Median Overall Survival
40%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
40%
Clinical Trials
20%
Israeli
20%
Smokers
20%
Multivariate Analysis
20%
Consecutive Patients
20%
Poor Prognosis
20%
Liver Metastasis
20%
Univariate Analysis
20%
Safety Profile
20%
Brain Metastases
20%
Progression-free Survival
20%
Median Survival
20%
Non-small Cell Lung Cancer (NSCLC)
20%
Cox Proportional Hazards Regression Model
20%
Overall Survival of Patients
20%
Response Evaluation Criteria in Solid Tumors (RECIST)
20%
Regulatory Approval
20%
January 2015
20%
Treatment Line
20%
Cancer Center
20%
Non-squamous
20%
Pericarditis
20%
Febrile Neutropenia
20%
Median Progression-free Survival
20%
Pseudoprogression
20%
Medicine and Dentistry
Nivolumab
100%
Overall Survival
100%
Non Small Cell Lung Cancer
100%
Electrocorticography
100%
Progression Free Survival
40%
Malignant Neoplasm
20%
Multivariate Analysis
20%
Proportional Hazards Model
20%
Clinical Trial
20%
Liver Metastasis
20%
Univariate Analysis
20%
Brain Metastasis
20%
Pericarditis
20%
Febrile Neutropenia
20%
Treatment of Non-Small Cell Lung Cancer
20%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Non Small Cell Lung Cancer
100%
Nivolumab
100%
Progression Free Survival
40%
Clinical Trial
20%
Malignant Neoplasm
20%
Liver Metastasis
20%
Brain Metastasis
20%
Pericarditis
20%
Febrile Neutropenia
20%
Immunology and Microbiology
Nivolumab
100%
Overall Survival
100%
Progression Free Survival
40%
Pericarditis
20%